Compare SCL & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCL | CTMX |
|---|---|---|
| Founded | 1932 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 977.1M |
| IPO Year | 1994 | 2015 |
| Metric | SCL | CTMX |
|---|---|---|
| Price | $51.70 | $4.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $75.00 | $12.10 |
| AVG Volume (30 Days) | 119.9K | ★ 10.8M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $1,803,737,000.00 | $76,201,000.00 |
| Revenue This Year | $6.60 | N/A |
| Revenue Next Year | $5.27 | $18.75 |
| P/E Ratio | $24.11 | ★ $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $41.82 | $0.48 |
| 52 Week High | $68.00 | $8.21 |
| Indicator | SCL | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 58.06 | 42.66 |
| Support Level | $47.21 | $3.89 |
| Resistance Level | $52.57 | $4.54 |
| Average True Range (ATR) | 1.32 | 0.34 |
| MACD | 0.65 | -0.01 |
| Stochastic Oscillator | 99.61 | 14.49 |
Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. The majority of Stepan's revenue comes from the United States, followed by France, Poland, the United Kingdom, Brazil, Mexico, and other countries.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.